Publication | Closed Access

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study

Chronic PhaseHematological MalignancyChronic Myeloid LeukemiaOncologyHematologyPharmacologyImatinib-intolerant PatientsMedicineMyeloid Neoplasia